Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8IUH8

UPID:
SPP2C_HUMAN

ALTERNATIVE NAMES:
Intramembrane protease 5

ALTERNATIVE UPACC:
Q8IUH8; Q8TC67; Q8WVZ6

BACKGROUND:
The protein Signal peptide peptidase-like 2C, alternatively named Intramembrane protease 5, is pivotal in male fertility, specifically in the processes of spermatogenesis and acrosome formation. It cleaves specific proteins, thereby modulating Ca(2+) homeostasis and vesicular trafficking. Additionally, it acts as a scaffold protein, aiding in the assembly of the IZUMO1 complex, crucial for sperm-egg fusion.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Signal peptide peptidase-like 2C unveils potential avenues for developing novel fertility treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.